X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor. It is discovered and selected as a lead candidate for the treatment of breast cancer.
Lead Product(s): OP-3136
Therapeutic Area: Oncology Product Name: OP-3136
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aurigene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Under the collaboration, Novartis will increase the size of the ongoing Phase 1/2 study testing OP-1250 (palazestrant), an orally-available small molecule with dual activity as both a complete ER antagonist and a selective ER degrader, in combination with ribociclib.
Lead Product(s): Palazestrant,Ribociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 10, 2023
Details:
Olema intends to use the net proceeds to fund research and development of palazestrant OP-1250 (palazestrant), a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist and a selective ER degrader.
Lead Product(s): Palazestrant,Palbociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Paradigm BioCapital
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 05, 2023
Details:
OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), which is being investigated in combination with palbociclib, a CDK4/6 inhibitor, for the treatment of ER+/HER2- metastatic breast cancer.
Lead Product(s): OP-1250,Palbociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
OP-1250 demonstrated favorable pharmacokinetics characterized by high oral bioavailability, dose proportional exposure and a long half-life of eight days, with steady-state plasma levels showing minimal peak-to-trough variability, enabling consistent inhibition of ER.
Lead Product(s): OP-1250,Palbociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).
Lead Product(s): OP-1250
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).
Lead Product(s): OP-1250
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).
Lead Product(s): OP-1250
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
Under the terms of the agreement, Olema and Aurigene will jointly direct preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Aurigene
Deal Size: $438.0 million Upfront Cash: $8.0 million
Deal Type: Collaboration June 09, 2022
Details:
OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD).
Lead Product(s): OP-1250,Palbociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
